GERN Posts Earnings After a Brutal Week

Geron Corporation has just delivered its Q3 earnings report with the stock down 19% on the week, sitting at $0.93, and analysts cutting targets into the print.

The analyst picture tells the clearest story of the past few days. Two firms moved in quick succession. Wedbush lowered its target from $6 to $5 on October 29 while keeping its Outperform rating. Needham cut harder, dropping from $4 to $2.50 while holding its Buy. Both reductions came within 24 hours of each other and together bring the consensus mean target to $3.63, nearly four times the current price. That gap is wide enough to reflect a range of outcomes, from genuine recovery potential to a Street that has not yet fully re-rated to the new trading level. Goldman Sachs reinstated with a Sell and a $1 target back in July 2025, a note that looks prescient at current levels, though it predates the EU approval of Rytelo.

The bears have had the better of the argument recently. The stock has shed 22.5% over the past month and 19% in this past week alone. The bear case centres on flat near-term revenues, the delayed IMpactMF trial readout and a pipeline of execution risks that includes safety signals, efficacy uncertainty and regulatory hurdles. The bull case rests on the EU approval of Rytelo for low-risk myelodysplastic syndrome, which opened a new revenue stream in 2026, and the company's claim that disease modification data for imetelstat gives it a durable commercial platform. Factor scores complicate the read: EPS momentum is strong, ranking in the 96th percentile over 30 days and 93rd on EPS surprise, but the short score sits in just the 25th percentile, meaning most comparable names carry a lighter short burden.

Short interest, while elevated at 11.4% of the free float, is actually easing rather than building. It has fallen roughly 8.4% over the past month and drifted down from the peak of around 18% of float seen in mid-September. The ORTEX short score has also declined from 64 at the time of the previous note to 58.9 now, a meaningful drop that suggests some bears have taken profits into the weakness rather than pressing the position. The previous note flagged that shorts were rebuilding ahead of the November 4 earnings; that rebuilding has since partially reversed. Borrow conditions remain loose. Availability is running at 643% of short interest, up 41% on the week, meaning there are more than six shares available to lend for every one currently borrowed. Cost to borrow has fallen to 0.33%, down 16% on the week. The borrow market is not signalling any squeeze pressure.

Options positioning reinforces the lack of urgency. The put/call ratio is 0.27, fractionally below its 20-day average of 0.28, and the z-score is -2.47. That means options traders are running below their recent average in put protection, an unusually call-skewed reading for a stock that just had a rough month. The 52-week low on the PCR is 0.05, and the high is 0.57; the current reading is well inside that range but closer to the bottom than the top.

On the ownership register, RA Capital held 9.9% as last disclosed in August, Soleus disclosed 6.5% in May and State Street filed a fresh 13G in August at 5.6%. BlackRock added 1.8 million shares in the September quarter. None of the holders on the 13D/G register have filed activist intent; all positions are Schedule 13G, and as the standard disclosure applies, holders who have dropped below 5% since filing are not required to update. The insider log is thin on conviction: the most recent transactions are small director compensation grants and a CFO option exercise paired with tax-withholding sale in February.

With the earnings print now live, the focus shifts to what management says about Rytelo uptake in Europe, the revised timeline for IMpactMF data and whether the flat-revenue trend has shown any early break.